Stomach (gastric) cancer arises from the stomach lining and often presents late because early symptoms are subtle. Major risk factors include H. pylori infection, dietary factors, smoking, and inherited mutations such as CDH1. Diagnosis requires endoscopy with biopsy and staging with imaging and endoscopic ultrasound. Treatment is stage-dependent and ranges from endoscopic removal for very early tumors to surgery, chemotherapy, targeted agents, and immunotherapy for advanced disease. Screening programs in high-incidence countries detect cancers earlier and improve outcomes.
What is stomach (gastric) cancer?
Stomach cancer, also called gastric cancer, is a malignant tumor that arises from the lining of the stomach. It can grow locally and spread (metastasize) to nearby organs, lymph nodes, the liver, and occasionally distant sites. Worldwide, most gastric cancers are adenocarcinomas that develop from the stomach's glandular cells.
Risk factors
Several factors increase the chance of developing gastric cancer:
- Helicobacter pylori infection - one of the strongest and most common risk factors.
- Diets high in salted, smoked, or preserved foods and low in fresh fruits and vegetables.
- Tobacco smoking.
- Older age and male sex.
- Family history and hereditary syndromes (for example, hereditary diffuse gastric cancer associated with CDH1 mutations).
- Epstein-Barr virus (EBV) in a subset of tumors.
Symptoms
Early-stage stomach cancer often causes no clear symptoms. When symptoms appear they can be non-specific and include:
- Indigestion, heartburn, or early fullness after eating.
- Loss of appetite and unintended weight loss.
- Upper abdominal discomfort or pain, nausea, or vomiting.
- Anemia-related fatigue from slow internal bleeding.
Diagnosis and staging
An upper endoscopy (esophagogastroduodenoscopy) with biopsy is the definitive test to diagnose gastric cancer. Pathology identifies the tumor type and helps guide treatment.
Once confirmed, clinicians stage the cancer to guide therapy. Typical staging tools include contrast CT scans of the chest/abdomen/pelvis, endoscopic ultrasound (to assess depth of invasion and regional lymph nodes), diagnostic laparoscopy in selected cases, and blood tests (including check for anemia). Molecular testing of tumor tissue (HER2, microsatellite instability/MSI, and others) increasingly informs targeted and immune-based treatments.
Treatment overview
Treatment depends on the cancer's stage, location, and molecular features, plus the patient's overall health.
Early-stage
Very early tumors confined to the mucosa or superficial submucosa may be removed endoscopically using endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). Surgical resection (partial or total gastrectomy) with appropriate lymph node removal remains the standard for localized disease.
Locally advanced and resectable disease
Multimodal therapy - neoadjuvant (preoperative) chemotherapy or chemoradiation followed by surgery, and sometimes adjuvant treatment - improves outcomes compared with surgery alone.
Advanced or metastatic disease
Systemic therapy is the mainstay. Chemotherapy regimens remain central. Targeted agents (for example, trastuzumab for HER2-positive tumors, agents targeting VEGF pathways) and immune checkpoint inhibitors are options for selected patients based on tumor biomarkers. Palliative surgery, radiation, or endoscopic procedures can relieve symptoms.
Follow-up and supportive care, including nutrition support, play key roles across all stages. In countries with high incidence (for example, Japan and South Korea), organized endoscopic screening programs detect many cancers earlier and improve survival outcomes.